Connection
Pavel Jedlicka to Bone Neoplasms
This is a "connection" page, showing publications Pavel Jedlicka has written about Bone Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.224 |
|
|
|
-
Jedlicka P. The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers. Expert Opin Ther Targets. 2017 11; 21(11):997-999.
Score: 0.525
-
Parrish JK, Sechler M, Winn RA, Jedlicka P. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene. 2015 Jan 08; 34(2):257-62.
Score: 0.403
-
Moore C, Parrish JK, Jedlicka P. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth. PLoS One. 2017; 12(5):e0178028.
Score: 0.128
-
Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res. 2012 Aug; 10(8):1098-108.
Score: 0.091
-
Jedlicka P. Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol. 2010 Mar 19; 3(4):338-47.
Score: 0.078